Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* T1DM patients aged 12-18 years with at least 5 years disease duration defined according to the criteria of International Society for Pediatric and Adolescent Diabetes (ISPAD) .~* Patients on insulin pump therapy using Medtronic advanced hybrid closed system (Medtronic, Northridge, USA) with Guardian™ 3 sensor or Guardian™ 4 sensor and Guardian link transmitter initiated at least 6 months before the study, patients with minimum daily insulin requirement of more than 8 units, willingness and ability to adhere to the study protocol, and access to the internet as well as a computer system that met requirements for uploading the study pump data.~* Active diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion ) 30-299 mg/g creatinine in two of three samples over a 3- to 6-months period despite angiotensin converting enzyme inhibitors).~* Hemoglobin A1c (HbA1c) ≤8.5%.~* Patients on regular visits to clinic.~Exclusion Criteria:~* patients with other diabetic microvascular complications (neuropathy or retinopathy) or with macrovascular complications.~* Patients with history of liver disease or any disorder likely to impair liver functions or elevated liver enzymes.~* Patients with any evidence of renal impairment due to causes other than diabetes.~* Patients with hypertension.~* Hepatitis virus infection (B or C) or any evidence of infection~* Participation in a previous investigational drug study within 3 months preceding screening.~* Hypoglycemic unawareness or recurrent severe hypoglycemic episodes in the last 6 months prior to recruitment.~* Recurrent diabetic ketoacidosis (DKA) (more than 2 episodes in the previous 6 months).~* Taking other oral hypoglycemic medications which could affect blood glucose.~* Patients with known allergy to sitagliptin.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Oral sitagliptin 50 mg supplementation for three months (Type: ACTIVE_COMPARATOR): Intervention group includes: adolescents with diabetic nephropathy on advanced hybrid closed loop system receiving oral sitagliptin 50 mg for three months on a daily basis
- Control group ( No intake of oral sitagliptin 50 mg supplementation for three months) (Type: NO_INTERVENTION): Control group includes: adolescents with diabetic nephropathy on advanced hybrid closed loop system who did not take oral sitagliptin 50 mg for three months on a daily basis

Based on this trial design, predict the completion outcome and termination type (if applicable).